Impact of Timely Switching From Imatinib to a Second-Generation Tyrosine Kinase Inhibitor After 12-Month Complete Cytogenetic Response Failure: A Chart Review Analysis

O'Brien, 2003, Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia, N Engl J Med, 348, 994, 10.1056/NEJMoa022457 Kantarjian, 2012, Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience, Blood, 119, 1981, 10.1182/blood-2011-08-358135 Shah, 2004, Overriding imatinib resistance with a novel ABL kinase inhibitor, Science, 305, 399, 10.1126/science.1099480 Hughes, 2003, Frequency of major molecular responses to imatinib or interferon alpha plus cytarabine in newly diagnosed chronic myeloid leukemia, N Engl J Med, 349, 1423, 10.1056/NEJMoa030513 Kantarjian, 2007, Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial, Blood, 109, 5143, 10.1182/blood-2006-11-056028 Kantarjian, 2007, Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance, Blood, 110, 3540, 10.1182/blood-2007-03-080689 Hochhaus, 2008, Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib, Leukemia, 22, 1200, 10.1038/leu.2008.84 Jabbour, 2011, The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors, Blood, 118, 4541, 10.1182/blood-2011-04-348110 Druker, 2006, Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia, N Engl J Med, 355, 2408, 10.1056/NEJMoa062867 de Lavallade, 2008, Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis, J Clin Oncol, 26, 3358, 10.1200/JCO.2007.15.8154 National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia (v2.2012). Available at: http://www.nccn.org. Accessed: December 20, 2013. Baccarani, 2009, Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet, J Clin Oncol, 27, 6041, 10.1200/JCO.2009.25.0779 Hanfstein, 2012, Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia, Leukemia, 26, 2096, 10.1038/leu.2012.85 Chen, 2012, Monitoring and switching patterns of patients with chronic myeloid leukemia treated with imatinib in community settings: a chart review analysis, Curr Med Res Opin, 28, 1, 10.1185/03007995.2012.741577 National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia (v1.2013). Available at: http://www.nccn.org. Accessed: December 20, 2013. Baccarani, 2013, European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013, Blood, 122, 872, 10.1182/blood-2013-05-501569